You are here: Industry Insights > small molecule

News List

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
Block-buster Small Molecule Pharmaceuticals Approved by the NMPA in 2023 Yefenghong
March 06, 2024
According to data collated from the National Medical Products Administration (NMPA) official website, a total of more than 80 new drugs were granted inaugural approval within the domestic market.
Breakthrough in Research of Small Molecule Drugs against SARS-CoV-2 PharmaSources/Xiaonisha
March 21, 2022
Corona virus disease 2019 (COVID-19) caused by a novel single-stranded RNA coronavirus has swept the world. The International Committee on Taxonomy of Viruses (ICTV) named the virus SARS-CoV-2.
Human trial data of oral small molecule PD-1/PD-L1 inhibitors were first released PharmaSources/Xiaoyaowan
December 02, 2021
Recently, Incyte of the United States reported the Phase I clinical data of oral small molecule PD-L1 inhibitor INCB086550 in Journal for ImmunoTherapy of Cancer.
Small Molecule and Great Potential: Oral Small Molecule COVID-19 Pharmaceutical Chemicals PharmaSources/Xiaoyaowan
October 28, 2021
Recently, MSD announced to initiate the Phase III clinical trial of its oral small molecule COVID-19 drug - Molnupiravir (MK-4482).
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics WorldPharmaNews
January 13, 2022
Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors prnasia
January 10, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19 AmericanPharmaceuticalReview
December 09, 2021
Sosei Group Corporation announced it has received grant funding from Wellcome, through the COVID-19 Therapeutics Accelerator. The funding will be used to advance the pre-clinical development of the Company's novel oral anti-viral small molecules ...
Insilico Medicine and Usynova Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drugs with AI prnasia
August 05, 2021
Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, and Usynova announced to reach strategic cooperation in advancing the development of novel therapies.
A small molecule induces readthrough of cystic fibrosis CFTR nonsense mutations July 20, 2021
An experimental drug reported in Nature Communications suggests that a "path is clearly achievable" to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations.